Provided by Tiger Trade Technology Pte. Ltd.

Eledon Pharmaceuticals, Inc.

2.79
+0.00500.18%
Volume:281.18K
Turnover:780.84K
Market Cap:226.31M
PE:-2.82
High:2.86
Open:2.86
Low:2.75
Close:2.78
52wk High:4.60
52wk Low:1.35
Shares:81.26M
Float Shares:74.57M
Volume Ratio:0.43
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9867
EPS(LYR):-0.5566
ROE:-110.71%
ROA:-39.02%
PB:3.14
PE(LYR):-5.00

Loading ...

Sep 30, 2024

Correspondence

Form CORRESP - Correspondence
Sep 20, 2024

Major Issues Report

Form 8-K - Current report
Aug 19, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 19, 2024

[Rev.]Quaterly Report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
Aug 19, 2024

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Aug 14, 2024

Major Issues Report

Form 8-K - Current report
Jul 12, 2024

Major Issues Report

Form 8-K - Current report
Jul 10, 2024

Major Issues Report

Form 8-K - Current report
Jul 10, 2024

Major Issues Report

Form 8-K - Current report
Jun 03, 2024

Correspondence

Form CORRESP - Correspondence
May 15, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2024

Major Issues Report

Form 8-K - Current report
May 07, 2024

Major Issues Report

Form 8-K - Current report
Apr 26, 2024

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Mar 28, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 28, 2024

Major Issues Report

Form 8-K - Current report
Feb 15, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Nov 10, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]